ReviewHuman genetics2025
Regulating genome language models: navigating policy challenges at the intersection of AI and genetics.
Review in Human genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- AI in variant analysis: fast track to genetic diagnoses.Human genetics · 2026Review
- Improving governance in the age of synthetic biology, artificial intelligence, and diverging threats.Frontiers in bioengineering and biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Genome Language Models (GLMs) represent a transformative convergence of artificial intelligence (AI) and genomics, offering unprecedented capabilities for biological discovery, healthcare innovation, and therapeutic design applications. However, these powerful tools create novel regulatory challenges that existing frameworks-whether AI governance or genomic privacy protections-cannot adequately address alone. This paper examines the critical regulatory gaps emerging at this intersection, highlighting tensions between AI principles that favor broad data access and genomic governance that demands stringent privacy protections and informed consent. We analyze how GLMs challenge conventional regulatory approaches as they pertain to applications in disease risk prediction, international research collaboration, and open-source model distribution. We propose a multilayered governance framework that combines policy innovations such as regulatory sandboxes and certification frameworks with technical solutions for privacy preservation and model interpretability. By developing adaptive governance strategies that bridge AI and genomic regulation, we can enable responsible GLM innovation while safeguarding individual rights, promoting equity, and addressing emerging biosecurity concerns in this rapidly evolving field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.